Active, not recruitingPHASE1, PHASE2NCT04408625
Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
Studying Frontotemporal dementia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Prevail Therapeutics
- Principal Investigator
- Travis Lewis, MD, PhDPrevail Therapeutics
- Intervention
- LY3884963(biological)
- Enrollment
- 35 enrolled
- Eligibility
- 30-85 years · All sexes
- Timeline
- 2020 – 2029
Study locations (12)
- k2 Medical Research-Maitland, Maitland, Florida, United States
- PPD Phase 1 Clinic, 100 West Gore Street, Suite 202, Orlando, Florida, United States
- Lahey Hospital & Medical Center, 41 Burlington Mall Road, Burlington, Massachusetts, United States
- Hospital of the University of Pennsylvania, 3 West Gates Building, 3400 Spruce Street, Philadelphia, Pennsylvania, United States
- Royal Prince Alfred Hospital, Brain & Mind Research Institute, 94 Mallet Street, Camperdown, New South Wales, Australia
- UZ Leuven, Neurologie Herestraat 49, Leuven, Belgium
- AP-HM Hôpital de La Timone, Saint-Pierre, Marseille, France
- Centre Mémoire de Ressources, Lille, France
- Le Ber, Institut du Cerveau et de la Moelle Epinière, Paris, France
- Hospital Clinic de Barcelona, Villaroel 170 Servicio de Neurología, Barcelona, Spain
- Hospital Universitario de Donostia, Servicio De Neurologia, Consultas Externas Neurologia, San Sebastian, Guipúzcoa, Donostia / San Sebastian, Spain
- University College London,Queen Square, Dementia Research Building, London,, London, United Kingdom
Collaborators
Eli Lilly and Company
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04408625 on ClinicalTrials.govOther trials for Frontotemporal dementia
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07239843Prospective Observational Study of the Relationship Between Sociodemographic Factors, Blood-based Biomarkers and Psychiatric Symptoms in Neurodegenerative Diseases and Mental DisordersFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- RECRUITINGNCT06856850Disease Biosignatures in ALS/FTD Spectrum: New Impactful Biological Perspectives Beyond Clinical ApproachesFondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- RECRUITINGNCT06803784Discovery and Validation of Protein Structural Complexes in Circulating Biofluids As Novel Biomarkers for Early Diagnosis, Prognosis and Therapeutic Management of Patients Affected by Neurodegenerative DisordersNeuromed IRCCS
- ENROLLING BY INVITATIONNCT07234851Understanding Mechanisms of Synaptic Degeneration Underlying Clinical Symptoms in Patients With MDs and NDs.Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- ACTIVE NOT RECRUITINGNANCT06768996Music, Social Attention, and DementiaUniversity of California, San Francisco
- RECRUITINGNANCT06668610A Multifocal TDCS-EEG Protocol for Improving Symptoms of Mild Cognitive Impairment and Early DementiaUniversity of Campania Luigi Vanvitelli
- RECRUITINGEARLY PHASE1NCT06511752Educational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive AphasiaUniversity of Texas at Austin
- RECRUITINGNCT06528964Proteinopathies Expression in Skin of Neurodegenerative DisordersUniversidad Autonoma de San Luis Potosí